{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:06:21Z","timestamp":1782187581921,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01NS100947"],"award-info":[{"award-number":["R01NS100947"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R21NS109687"],"award-info":[{"award-number":["R21NS109687"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R61NS124923"],"award-info":[{"award-number":["R61NS124923"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Brain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Status epilepticus (SE) in humans is characterized by prolonged convulsive seizures that are generalized and often difficult to control. The current antiseizure drugs (ASDs) aim to stop seizures quickly enough to prevent the SE-induced brain inflammation, injury, and long-term sequelae. However, sole reliance on acute therapies is imprudent because prompt treatment may not always be possible under certain circumstances. The pathophysiological mechanisms underlying the devastating consequences of SE are presumably associated with neuroinflammatory reactions, where prostaglandin E2 (PGE<jats:sub>2<\/jats:sub>) plays a pivotal role. As the terminal synthase for pathogenic PGE<jats:sub>2<\/jats:sub>, the microsomal prostaglandin E synthase-1 (mPGES-1) is rapidly and robustly induced by prolonged seizures. Congenital deletion of mPGES-1 in mice is neuroprotective and blunts gliosis following chemoconvulsant seizures, suggesting the feasibility of mPGES-1 as a potential antiepileptic target. Herein, we investigated the effects of a dual species mPGES-1 inhibitor in a mouse pilocarpine model of SE. Treatment with the mPGES-1 inhibitor in mice after SE that was terminated by diazepam, a fast-acting benzodiazepine, time-dependently abolished the SE-induced PGE<jats:sub>2<\/jats:sub> within the brain. Its negligible effects on cyclooxygenases, the enzymes responsible for the initial step of PGE<jats:sub>2<\/jats:sub> biosynthesis, validated its specificity to mPGES-1. Post-SE inhibition of mPGES-1 also blunted proinflammatory cytokines and reactive gliosis in the hippocampus and broadly prevented neuronal damage in a number of brain areas. Thus, pharmacological inhibition of mPGES-1 by small-molecule inhibitors might provide an adjunctive strategy that can be implemented hours after SE, together with first-line ASDs, to reduce SE-provoked brain inflammation and injury.\n<\/jats:p>","DOI":"10.1186\/s13041-023-01008-y","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T04:41:27Z","timestamp":1674621687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Transient inhibition of microsomal prostaglandin E synthase-1 after status epilepticus blunts brain inflammation and is neuroprotective"],"prefix":"10.1186","volume":"16","author":[{"given":"Nelufar","family":"Yasmen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison N.","family":"Sluter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lexiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3955-8928","authenticated-orcid":false,"given":"Jianxiong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"1008_CR1","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/epi.13121","volume":"56","author":"E Trinka","year":"2015","unstructured":"Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus\u2014report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56:1515\u201323. https:\/\/doi.org\/10.1111\/epi.13121.","journal-title":"Epilepsia"},{"key":"1008_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","volume":"14","author":"JP Betjemann","year":"2015","unstructured":"Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015;14:615\u201324. https:\/\/doi.org\/10.1016\/S1474-4422(15)00042-3.","journal-title":"Lancet Neurol"},{"key":"1008_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ana.24986","volume":"82","author":"CE Hill","year":"2017","unstructured":"Hill CE, Parikh AO, Ellis C, Myers JS, Litt B. Timing is everything: where status epilepticus treatment fails. Ann Neurol. 2017;82:155\u201365. https:\/\/doi.org\/10.1002\/ana.24986.","journal-title":"Ann Neurol"},{"key":"1008_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev-pharmtox-010814-124607","volume":"55","author":"NH Varvel","year":"2015","unstructured":"Varvel NH, Jiang J, Dingledine R. Candidate drug targets for prevention or modification of epilepsy. Annu Rev Pharmacol Toxicol. 2015;55:229\u201347. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010814-124607.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1008_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1586\/14737175.2015.1079130","volume":"15","author":"A Vezzani","year":"2015","unstructured":"Vezzani A, Dingledine R, Rossetti AO. Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. Expert Rev Neurother. 2015;15:1081\u201392. https:\/\/doi.org\/10.1586\/14737175.2015.1079130.","journal-title":"Expert Rev Neurother"},{"key":"1008_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.tips.2016.03.001","volume":"37","author":"A Dey","year":"2016","unstructured":"Dey A, Kang X, Qiu J, Du Y, Jiang J. Anti-inflammatory small molecules to treat seizures and epilepsy: from bench to bedside. Trends Pharmacol Sci. 2016;37:463\u201384. https:\/\/doi.org\/10.1016\/j.tips.2016.03.001.","journal-title":"Trends Pharmacol Sci"},{"issue":"Suppl 3","key":"1008_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/epi.13783","volume":"58","author":"E Aronica","year":"2017","unstructured":"Aronica E, Bauer S, Bozzi Y, Caleo M, Dingledine R, Gorter JA, et al. Neuroinflammatory targets and treatments for epilepsy validated in experimental models. Epilepsia. 2017;58(Suppl 3):27\u201338. https:\/\/doi.org\/10.1111\/epi.13783.","journal-title":"Epilepsia"},{"key":"1008_CR8","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1124\/pr.120.019539","volume":"72","author":"W Loscher","year":"2020","unstructured":"Loscher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72:606\u201338. https:\/\/doi.org\/10.1124\/pr.120.019539.","journal-title":"Pharmacol Rev"},{"key":"1008_CR9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/epi4.12409","volume":"5","author":"Y Yu","year":"2020","unstructured":"Yu Y, Jiang J. COX-2\/PGE(2) axis regulates hippocampal BDNF\/TrkB signaling via EP2 receptor after prolonged seizures. Epilepsia Open. 2020;5:418\u201331. https:\/\/doi.org\/10.1002\/epi4.12409.","journal-title":"Epilepsia Open"},{"key":"1008_CR10","doi-asserted-by":"publisher","first-page":"13966","DOI":"10.1096\/fj.201901460RR","volume":"33","author":"ELB Soldner","year":"2019","unstructured":"Soldner ELB, Hartz AMS, Akanuma SI, Pekcec A, Doods H, Kryscio RJ, et al. Inhibition of human microsomal PGE2 synthase-1 reduces seizure-induced increases of P-glycoprotein expression and activity at the blood-brain barrier. FASEB J. 2019;33:13966\u201381. https:\/\/doi.org\/10.1096\/fj.201901460RR.","journal-title":"FASEB J"},{"key":"1008_CR11","doi-asserted-by":"publisher","first-page":"11790","DOI":"10.1073\/pnas.0604400103","volume":"103","author":"Y Ikeda-Matsuo","year":"2006","unstructured":"Ikeda-Matsuo Y, Ota A, Fukada T, Uematsu S, Akira S, Sasaki Y. Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. Proc Natl Acad Sci U S A. 2006;103:11790\u20135. https:\/\/doi.org\/10.1073\/pnas.0604400103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1008_CR12","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/j.1476-5381.2009.00595.x","volume":"159","author":"Y Ikeda-Matsuo","year":"2010","unstructured":"Ikeda-Matsuo Y, Hirayama Y, Ota A, Uematsu S, Akira S, Sasaki Y. Microsomal prostaglandin E synthase-1 and cyclooxygenase-2 are both required for ischaemic excitotoxicity. Br J Pharmacol. 2010;159:1174\u201386. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00595.x.","journal-title":"Br J Pharmacol"},{"key":"1008_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jnr.22195","volume":"88","author":"T Takemiya","year":"2010","unstructured":"Takemiya T, Matsumura K, Sugiura H, Maehara M, Yasuda S, Uematsu S, et al. Endothelial microsomal prostaglandin E synthase-1 exacerbates neuronal loss induced by kainate. J Neurosci Res. 2010;88:381\u201390. https:\/\/doi.org\/10.1002\/jnr.22195.","journal-title":"J Neurosci Res"},{"key":"1008_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.neuint.2011.01.003","volume":"58","author":"T Takemiya","year":"2011","unstructured":"Takemiya T, Matsumura K, Sugiura H, Yasuda S, Uematsu S, Akira S, et al. Endothelial microsomal prostaglandin E synthase-1 facilitates neurotoxicity by elevating astrocytic Ca2+ levels. Neurochem Int. 2011;58:489\u201396. https:\/\/doi.org\/10.1016\/j.neuint.2011.01.003.","journal-title":"Neurochem Int"},{"key":"1008_CR15","doi-asserted-by":"publisher","first-page":"901902","DOI":"10.1155\/2014\/901902","volume":"2014","author":"T Shimada","year":"2014","unstructured":"Shimada T, Takemiya T, Sugiura H, Yamagata K. Role of inflammatory mediators in the pathogenesis of epilepsy. Mediators Inflamm. 2014;2014:901902. https:\/\/doi.org\/10.1155\/2014\/901902.","journal-title":"Mediators Inflamm."},{"key":"1008_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.06.022","volume":"98","author":"A Koeberle","year":"2015","unstructured":"Koeberle A, Werz O. Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders. Biochem Pharmacol. 2015;98:1\u201315. https:\/\/doi.org\/10.1016\/j.bcp.2015.06.022.","journal-title":"Biochem Pharmacol"},{"key":"1008_CR17","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1016\/j.bmcl.2016.09.070","volume":"26","author":"EB Park","year":"2016","unstructured":"Park EB, Kim KJ, Jeong HR, Lee JK, Kim HJ, Lee HH, et al. Synthesis, structure determination, and biological evaluation of phenylsulfonyl hydrazide derivatives as potential anti-inflammatory agents. Bioorg Med Chem Lett. 2016;26:5193\u20137. https:\/\/doi.org\/10.1016\/j.bmcl.2016.09.070.","journal-title":"Bioorg Med Chem Lett"},{"key":"1008_CR18","doi-asserted-by":"publisher","first-page":"106347","DOI":"10.1016\/j.prostaglandins.2019.106347","volume":"144","author":"HH Lee","year":"2019","unstructured":"Lee HH, Moon Y, Shin JS, Lee JH, Kim TW, Jang C, et al. A novel mPGES-1 inhibitor alleviates inflammatory responses by downregulating PGE(2) in experimental models. Prostaglandins Other Lipid Mediat. 2019;144:106347. https:\/\/doi.org\/10.1016\/j.prostaglandins.2019.106347.","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"1008_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1586\/14737175.2016.1134322","volume":"16","author":"Y Du","year":"2016","unstructured":"Du Y, Kemper T, Qiu J, Jiang J. Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus. Expert Rev Neurother. 2016;16:123\u201330. https:\/\/doi.org\/10.1586\/14737175.2016.1134322.","journal-title":"Expert Rev Neurother"},{"key":"1008_CR20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/epi.17190","volume":"63","author":"MM Nagib","year":"2022","unstructured":"Nagib MM, Zhang S, Yasmen N, Li L, Hou R, Yu Y, et al. Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects. Epilepsia. 2022;63:1003\u201315. https:\/\/doi.org\/10.1111\/epi.17190.","journal-title":"Epilepsia"},{"key":"1008_CR21","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1111\/bph.14622","volume":"176","author":"J Qiu","year":"2019","unstructured":"Qiu J, Li Q, Bell KA, Yao X, Du Y, Zhang E, et al. Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth. Br J Pharmacol. 2019;176:1680\u201399. https:\/\/doi.org\/10.1111\/bph.14622.","journal-title":"Br J Pharmacol"},{"key":"1008_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s13311-022-01191-1","volume":"19","author":"L Li","year":"2022","unstructured":"Li L, Yasmen N, Hou R, Yang S, Lee JY, Hao J, et al. Inducible prostaglandin E synthase as a pharmacological target for ischemic stroke. Neurotherapeutics. 2022;19:366\u201385. https:\/\/doi.org\/10.1007\/s13311-022-01191-1.","journal-title":"Neurotherapeutics"},{"key":"1008_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s0006-8993(96)01387-x","volume":"751","author":"LC Schmued","year":"1997","unstructured":"Schmued LC, Albertson C, Slikker W Jr. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 1997;751:37\u201346. https:\/\/doi.org\/10.1016\/s0006-8993(96)01387-x.","journal-title":"Brain Res"},{"key":"1008_CR24","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1073\/pnas.1120195109","volume":"109","author":"J Jiang","year":"2012","unstructured":"Jiang J, Ganesh T, Du Y, Quan Y, Serrano G, Qui M, et al. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Natl Acad Sci U S A. 2012;109:3149\u201354. https:\/\/doi.org\/10.1073\/pnas.1120195109.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1008_CR25","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1073\/pnas.1218498110","volume":"110","author":"J Jiang","year":"2013","unstructured":"Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci U S A. 2013;110:3591\u20136. https:\/\/doi.org\/10.1073\/pnas.1218498110.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1008_CR26","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s12035-020-01923-4","volume":"57","author":"Y Yu","year":"2020","unstructured":"Yu Y, Li L, Nguyen DT, Mustafa SM, Moore BM, Jiang J. Inverse agonism of cannabinoid receptor type 2 confers anti-inflammatory and neuroprotective effects following status epilepticus. Mol Neurobiol. 2020;57:2830\u201345. https:\/\/doi.org\/10.1007\/s12035-020-01923-4.","journal-title":"Mol Neurobiol"},{"key":"1008_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nbd.2014.12.032","volume":"76","author":"J Jiang","year":"2015","unstructured":"Jiang J, Yang MS, Quan Y, Gueorguieva P, Ganesh T, Dingledine R. Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiol Dis. 2015;76:126\u201336. https:\/\/doi.org\/10.1016\/j.nbd.2014.12.032.","journal-title":"Neurobiol Dis"},{"key":"1008_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.neuropharm.2019.02.011","volume":"149","author":"J Jiang","year":"2019","unstructured":"Jiang J, Yu Y, Kinjo ER, Du Y, Nguyen HP, Dingledine R. Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury. Neuropharmacology. 2019;149:149\u201360. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.02.011.","journal-title":"Neuropharmacology"},{"key":"1008_CR29","doi-asserted-by":"publisher","unstructured":"Kelly ME, Coulter DA: The pilocarpine model of acquired epilepsy. In: Models of Seizures and Epilepsy. Pitk\u00e4nen A, Buckmaster PS, Galanopoulou AS, Mosh\u00e9 SL, eds. Academic Press; 2017: 625\u201336. https:\/\/doi.org\/10.1016\/b978-0-12-804066-9.00043-2.","DOI":"10.1016\/b978-0-12-804066-9.00043-2"},{"key":"1008_CR30","first-page":"391","volume":"13","author":"Q Wang","year":"2021","unstructured":"Wang Q, Li Y, Wu M, Huang S, Zhang A, Zhang Y, et al. Targeting microsomal prostaglandin E synthase 1 to develop drugs treating the inflammatory diseases. Am J Transl Res. 2021;13:391\u2013419.","journal-title":"Am J Transl Res."},{"key":"1008_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/glia.23006","volume":"65","author":"UB Eyo","year":"2017","unstructured":"Eyo UB, Murugan M, Wu LJ. Microglia-Neuron Communication in Epilepsy. Glia. 2017;65:5\u201318. https:\/\/doi.org\/10.1002\/glia.23006.","journal-title":"Glia"},{"issue":"Suppl 3","key":"1008_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/epi.13785","volume":"58","author":"ML Barker-Haliski","year":"2017","unstructured":"Barker-Haliski ML, Loscher W, White HS, Galanopoulou AS. Neuroinflammation in epileptogenesis: Insights and translational perspectives from new models of epilepsy. Epilepsia. 2017;58(Suppl 3):39\u201347. https:\/\/doi.org\/10.1111\/epi.13785.","journal-title":"Epilepsia"},{"key":"1008_CR33","doi-asserted-by":"publisher","first-page":"107742","DOI":"10.1016\/j.neuropharm.2019.107742","volume":"167","author":"G Terrone","year":"2020","unstructured":"Terrone G, Balosso S, Pauletti A, Ravizza T, Vezzani A. Inflammation and reactive oxygen species as disease modifiers in epilepsy. Neuropharmacology. 2020;167:107742. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107742.","journal-title":"Neuropharmacology"},{"key":"1008_CR34","doi-asserted-by":"publisher","first-page":"1074537","DOI":"10.3389\/fcell.2022.1074537","volume":"10","author":"J Jiang","year":"2022","unstructured":"Jiang J, Santhakumar V, Zhu X. Editorial: Neuroinflammation in acquired epilepsy. Front Cell Dev Biol. 2022;10:1074537. https:\/\/doi.org\/10.3389\/fcell.2022.1074537.","journal-title":"Front Cell Dev Biol"},{"key":"1008_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0079-6123(02)35033-7","volume":"135","author":"TZ Baram","year":"2002","unstructured":"Baram TZ, Eghbal-Ahmadi M, Bender RA. Is neuronal death required for seizure-induced epileptogenesis in the immature brain? Prog Brain Res. 2002;135:365\u201375. https:\/\/doi.org\/10.1016\/S0079-6123(02)35033-7.","journal-title":"Prog Brain Res"},{"key":"1008_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-94-017-8914-1_9","volume":"813","author":"R Dingledine","year":"2014","unstructured":"Dingledine R, Varvel NH, Dudek FE. When and how do seizures kill neurons, and is cell death relevant to epileptogenesis? Adv Exp Med Biol. 2014;813:109\u201322. https:\/\/doi.org\/10.1007\/978-94-017-8914-1_9.","journal-title":"Adv Exp Med Biol"},{"key":"1008_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/epi.12461","volume":"55","author":"A Rojas","year":"2014","unstructured":"Rojas A, Jiang J, Ganesh T, Yang MS, Lelutiu N, Gueorguieva P, et al. Cyclooxygenase-2 in epilepsy. Epilepsia. 2014;55:17\u201325. https:\/\/doi.org\/10.1111\/epi.12461.","journal-title":"Epilepsia"},{"key":"1008_CR38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/13543784.2019.1557147","volume":"28","author":"A Dhir","year":"2019","unstructured":"Dhir A. An update of cyclooxygenase (COX)-inhibitors in epilepsy disorders. Expert Opin Investig Drugs. 2019;28:191\u2013205. https:\/\/doi.org\/10.1080\/13543784.2019.1557147.","journal-title":"Expert Opin Investig Drugs"},{"key":"1008_CR39","doi-asserted-by":"publisher","first-page":"101682","DOI":"10.1016\/j.pneurobio.2019.101682","volume":"183","author":"Y Yu","year":"2019","unstructured":"Yu Y, Nguyen DT, Jiang J. G protein-coupled receptors in acquired epilepsy: druggability and translatability. Prog Neurobiol. 2019;183:101682. https:\/\/doi.org\/10.1016\/j.pneurobio.2019.101682.","journal-title":"Prog Neurobiol."},{"key":"1008_CR40","doi-asserted-by":"publisher","first-page":"114363","DOI":"10.1016\/j.bcp.2020.114363","volume":"184","author":"R Hou","year":"2021","unstructured":"Hou R, Yu Y, Jiang J. PGE2 receptors in detrusor muscle: Drugging the undruggable for urgency. Biochem Pharmacol. 2021;184:114363. https:\/\/doi.org\/10.1016\/j.bcp.2020.114363.","journal-title":"Biochem Pharmacol."},{"key":"1008_CR41","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/med.21744","volume":"41","author":"J Jiang","year":"2021","unstructured":"Jiang J, Yu Y. Small molecules targeting cyclooxygenase\/prostanoid cascade in experimental brain ischemia: Do they translate? Med Res Rev. 2021;41:828\u201357. https:\/\/doi.org\/10.1002\/med.21744.","journal-title":"Med Res Rev"},{"key":"1008_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-med-011209-153129","volume":"61","author":"T Grosser","year":"2010","unstructured":"Grosser T, Yu Y, Fitzgerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med. 2010;61:17\u201333. https:\/\/doi.org\/10.1146\/annurev-med-011209-153129.","journal-title":"Annu Rev Med"},{"key":"1008_CR43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.prostaglandins.2009.04.003","volume":"91","author":"K Andreasson","year":"2010","unstructured":"Andreasson K. Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat. 2010;91:104\u201312. https:\/\/doi.org\/10.1016\/j.prostaglandins.2009.04.003.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"1008_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.trecan.2016.12.002","volume":"3","author":"J Jiang","year":"2017","unstructured":"Jiang J, Qiu J, Li Q, Shi Z. Prostaglandin E2 signaling: alternative target for glioblastoma? Trends Cancer. 2017;3:75\u20138. https:\/\/doi.org\/10.1016\/j.trecan.2016.12.002.","journal-title":"Trends Cancer"},{"key":"1008_CR45","doi-asserted-by":"publisher","first-page":"105238","DOI":"10.1016\/j.phrs.2020.105238","volume":"163","author":"L Li","year":"2021","unstructured":"Li L, Sluter MN, Yu Y, Jiang J. Prostaglandin E receptors as targets for ischemic stroke: Novel evidence and molecular mechanisms of efficacy. Pharmacol Res. 2021;163:105238. https:\/\/doi.org\/10.1016\/j.phrs.2020.105238.","journal-title":"Pharmacol Res."},{"key":"1008_CR46","doi-asserted-by":"publisher","first-page":"107504","DOI":"10.1016\/j.pharmthera.2020.107504","volume":"209","author":"MM Nagib","year":"2020","unstructured":"Nagib MM, Yu Y, Jiang J. Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus. Pharmacol Ther. 2020;209:107504. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107504.","journal-title":"Pharmacol Ther."},{"key":"1008_CR47","doi-asserted-by":"publisher","first-page":"11816","DOI":"10.1021\/acs.jmedchem.1c00816","volume":"64","author":"MN Sluter","year":"2021","unstructured":"Sluter MN, Hou R, Li L, Yasmen N, Yu Y, Liu J, et al. EP2 antagonists (2011\u20132021): a decade\u2019s journey from discovery to therapeutics. J Med Chem. 2021;64:11816\u201336. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00816.","journal-title":"J Med Chem"},{"key":"1008_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1172\/JCI27291","volume":"116","author":"T Grosser","year":"2006","unstructured":"Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4\u201315. https:\/\/doi.org\/10.1172\/JCI27291.","journal-title":"J Clin Invest"},{"key":"1008_CR49","doi-asserted-by":"publisher","first-page":"111000","DOI":"10.1016\/j.celrep.2022.111000","volume":"39","author":"R Hou","year":"2022","unstructured":"Hou R, Yu Y, Sluter MN, Li L, Hao J, Fang J, et al. Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma. Cell Rep. 2022;39:111000. https:\/\/doi.org\/10.1016\/j.celrep.2022.111000.","journal-title":"Cell Rep"},{"key":"1008_CR50","doi-asserted-by":"publisher","first-page":"113966","DOI":"10.1016\/j.biopha.2022.113966","volume":"156","author":"R Hou","year":"2022","unstructured":"Hou R, Yu Y, Jiang J. Prostaglandin E2 in neuroblastoma: targeting synthesis or signaling? Biomed Pharmacother. 2022;156:113966. https:\/\/doi.org\/10.1016\/j.biopha.2022.113966.","journal-title":"Biomed Pharmacother."}],"container-title":["Molecular Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-023-01008-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13041-023-01008-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-023-01008-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T04:41:45Z","timestamp":1674621705000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularbrain.biomedcentral.com\/articles\/10.1186\/s13041-023-01008-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1008"],"URL":"https:\/\/doi.org\/10.1186\/s13041-023-01008-y","relation":{},"ISSN":["1756-6606"],"issn-type":[{"value":"1756-6606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Tennessee Health Science Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing or financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}